JP Morgan Chase
ADMA icon

JP Morgan Chase’s ADMA Biologics ADMA Stock Holding History

JP Morgan Chase’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-750,000
Closed -$6.86M – 7703
2026
Q1 		$6.86M Buy
+750,000
New +$11.8M ﹤0.01% 3026

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase's ADMA Position: Q2 2026 in Review

JP Morgan Chase reduced its ADMA Biologics (ADMA) stake by 46% in Q2 2026, selling an estimated $2.15M and leaving 276,724 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #4062.

JP Morgan Chase first reported a position in ADMA in Q1 2018 and has held it in 33 quarters since. The position peaked at $15.5M in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • JP Morgan Chase held 276,724 shares of ADMA Biologics worth $2.4M as of Q2 2026.
  • JP Morgan Chase sold 236,202 ADMA Biologics shares in Q2 2026, an estimated $2.15M.
  • ADMA Biologics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4062 holding.
  • JP Morgan Chase first reported a position in ADMA Biologics in Q1 2018 and has held it in 33 quarters since.
  • JP Morgan Chase's ADMA Biologics position peaked at $15.5M in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.